Thus, TFEB enhancers, such as Torin 1, a potent mammalian target of rapamycin (mTOR) inhibitor 29, and C1, a novel curcumin analog could be used as pharmacological approaches to treat PD [105]. Here, MTOR is linked to Parkinson disease.